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Abstract 
Background: Generic preference based measures (EQ-5D and SF-6D) can be used in the 
economic evaluation of mental health interventions. However there are inconsistent findings 
regarding the psychometric properties of the instruments. 
Aims: To investigate the psychometric performance of the measures across a range of 
mental health conditions using seven existing datasets. 
Methods: The feasibility, construct validity and responsiveness of the EQ-5D and SF-6D 
were assessed in comparison to condition specific indicators. 
Results: Strong evidence for validity and responsiveness in common mental health and 
personality disorder samples was found.  The psychometric performance in schizophrenia 
was more inconsistent. 
Conclusions: EQ-5D and SF-6D can be used in the economic evaluation of interventions for 
common mental health problems and personality disorders with some confidence. In 
schizophrenia, the measurement of quality of life may be improved by developing a 
condition-specific preference based measure. 
Declaration of interests: John Brazier developed SF-6D.  Michael Barkham developed the 
CORE-OM. 
  
Introduction 
Cost utility analysis (CUA) can be used to assess the cost effectiveness of interventions 
across mental health conditions, and is employed by agencies such as the National Institute 
for Health and Clinical Excellence (NICE) to inform the allocation of scarce resources.1 CUA 
uses the common metric of Quality Adjusted Life Years (QALYs) as the effect outcome 
measure - which combines values for the quantity and quality of life into a single score and 
allows comparisons across treatments for different conditions. To derive a value for health 
related quality of life (HRQL), or utility, generic preference-based measures of health (PBM) 
such as the EuroQol EQ-5D (EQ-5D)2,3 or Short Form-6D (SF-6D)4,5 can be used.  The utility 
score is derived from the preferences of the general population and is anchored on the 0-1 
dead-full health scale (where a score below zero is equivalent to a state worse than dead).  
Generic PBMs can be used in clinical trials alongside condition specific patient-reported 
outcome measures (PROMs) in order to assess both the comparative and cost effectiveness 
of interventions.   
 
With the significant increase in the use of economic appraisal for funding and reimbursement 
decision making, there has been interest in establishing the psychometric validity of generic 
PBMs for use in mental health disorders.  It has been found that both the EQ-5D and SF-6D 
demonstrate construct validity and responsiveness for depression, but the results for anxiety 
disorders are less convincing.6-9 Research in schizophrenia populations10 and individuals 
with psychosis11 found mixed evidence on the validity of generic PBMs.  For personality 
disorders research indicates that the EQ-5D may be related to condition specific indicators 
and be sensitive to changes in HRQL.12  
 
The inconsistent findings regarding the psychometric properties of the EQ-5D and SF-6D in 
mental health disorders suggests that further work is needed to establish the validity of the 
measures.  The aim of this study is to investigate the psychometric performance of both the 
EQ-5D and SF-6D across a range of mental health conditions including common mental 
health problems, schizophrenia, and personality disorders. Seven large datasets were used 
to assess the feasibility, validity, and responsiveness of the instruments to change over time 
in comparison to widely used and validated condition-specific PROMs. The current study 
complements prior work by pooling data from multiple sources and combining the evidence 
in an overview of the psychometric strengths and weaknesses of the EQ-5D and SF-6D for 
mental health disorders.    
 
Methods 
Identification of datasets  
A literature search was conducted to identify studies that have used the EQ-5D and/or the 
SF-6D in measuring treatment efficacy in anxiety, depression, schizophrenia and personality 
disorders9,10 as well as have included a condition specific measure. In total 69 authors of 
relevant studies were contacted with the request to use their datasets in the analysis. Of 
those, 12 datasets were received (17% of those requested), and these were reviewed for 
acceptable condition-specific comparison measures or clinical indicators.  Datasets from 
seven studies were selected for use in these analyses including (1) assessing health 
economics of antidepressants (AHEAD), (2) psychological interventions for postnatal 
depression (PONDeR), (3) improving access to psychological therapies cohort study (IAPT), 
(4) a trial of cognitive behaviour therapy versus treatment as usual for recurrent self harm 
(POPMACT), (5) quality of life following adherence therapy (QUATRO), (6) multi-centre 
study of art therapy in schizophrenia – systematic evaluation (MATISSE), and (7) the study 
on the cost-effectiveness of personality disorder treatment (SCEPTRE). The first three 
studies included samples with common mental health problems (n=3,512), the fourth study 
included mixed common mental health and personality disorder diagnoses leading to self-
harm (n=480), the next two studies (fifth and sixth) included schizophrenia (n=826) and the 
seventh study personality disorders (n=932)).  Of the five datasets excluded, three were 
excluded as they focused on general population samples, and two were excluded as they 
did not include a comparison measure of interest. The seven datasets are described in 
Table 1. 
 
Measures 
The generic PBMs were compared to a condition specific measure in each dataset. The 
measure pairs used in the analyses are detailed in Table 1. 
 
Generic preference based measures 
EQ-5D 
The EQ-5D2,3 is a widely used generic PBM and measures health status on five dimensions 
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with three 
associated response options (no problem, some problems, extreme problems). A selection 
of the 243 possible health states was valued by the general population using Time Trade Off 
(TTO) to produce a utility score for each health state (range -0.594 to 1).  The EQ-5D is the 
preferred instrument for use in submissions to the NICE appraisal process.1 
 
SF-6D  
The SF-6D4,5 is a generic PBM that generates 18,000 health states across six dimensions 
(physical functioning, role limitations, social functioning, pain, mental health, and vitality), 
with between four and six response options. The questionnaire is a short version of the SF-
36/SF-12.  The utility scale for the SF-6D was derived by valuing 249 states using Standard 
Gamble (SG) and ranges from 0.296 to 1.  It is accepted by a number of reimbursement 
agencies around the world including the Canadian Agency for Drugs and Technologies in 
Health,21 and the Australian Pharmaceutical Benefits Advisory Committee.22 
 
Condition specific measures  
Hospital Anxiety and Depression Scale (HADS) 
The HADS23 is a 14 item self-report measure that contains two seven item subscales: 
depression (HADS-D) and anxiety (HADS-A).  The total score for each dimension is 21 
(items are scored 0-3) with high scores indicative of increased levels of anxiety and 
depression (a score of 8+ indicates a possible case, and a score of 11+ indicates a probable 
case).  The overall score (HADS-T) is also used as a measure of global functioning. The 
HADS has been widely used across clinical groups and research settings, and there is 
evidence for its psychometric validity.24 In this study, HADS was used to assess the 
performance of the EQ-5D in two samples of people with mild and moderate anxiety and 
depression from the AHEAD and POPMACT trials. 
 
Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM) 
The CORE-OM25-29 is a self-report measure developed in the UK for routine use in 
psychological services.  CORE-OM comprises 34 items addressing domains of subjective 
well-being, symptoms (anxiety, depression, physical problems, trauma), functioning (general 
functioning, close relationships, social relationships), and risk (risk to self, risk to others). 
Items are scored on a 5-point, 0–4 scale.  CORE clinical scores are computed as the mean 
of all completed items multiplied by 10 (range 0-40).  The psychometric validity of the CORE-
OM has been demonstrated.30,31 In this study the CORE-OM was used to assess the 
psychometric performance of the SF-6D in two samples of people with mild and moderate 
anxiety and depression from the PONDeR and IAPT trials. 
 
Brief Psychiatric Rating Scale Expanded (BPRS-E) 
The BPRS32 was developed to assess symptom change in psychiatric inpatients and is one 
of the most widely used measures of psychotic and affective symptoms. The expanded 
version, BPRS–E which has 24 items developed for use in schizophrenia patients, was used 
in the current study. The BPRS-E is administered using semi-structured interviews and 
includes 24 items scored from 1 (not present) to 7 (extremely severe).  In this study the 
BPRS-E was used to assess the psychometric performance of the EQ-5D and SF-6D in a 
sample of patients with schizophrenia from the QUATRO trial. 
 
Positive and Negative Syndrome Scale (PANSS) 
The PANSS33,34 was developed to evaluate positive, negative, and other symptom 
dimensions in schizophrenia by combining the 18 items of the BPRS with the 12 items of the 
Psychopathology Rating Schedule with detailed instructions on completion by interview. The 
30 items are scored from 1 (absent) to 7 (extreme) and result in 3 subscales: positive, 
negative, and general psychopathology. The PANSS was used to assess the performance of 
the EQ-5D in a sample of patients with schizophrenia from the MATISSE trial. 
 
Structured Interview for DSM-IV Personality (SIDP-IV) 
Personality disorder diagnoses were assessed using the SIDP-IV.35 This instrument includes 
the 11 formal DSM-IV-TR Axis II diagnoses (e.g., schizoid personality disorder) including 
personality disorder mixed, the two DSM-IV-TR appendix diagnoses (depressive and 
negativistic personality disorder), and in addition the DSM-III-R self-defeating personality 
disorder. Items are scored on a 4 point, 0-3 scale, with scores of 2 and 3 indicating the 
presence of personality disorder traits. The SIDP-IV was used to assess the performance of 
the EQ-5D in a sample of patients with personality disorders from the SCEPTRE trial.  
 
Analysis 
Feasibility 
The feasibility of administering the measures to respondents was assessed in terms of the 
level of completion of each measure at baseline.  The baseline assessment was used since 
this was available for both the generic and the condition specific measures.  Completion is a 
simplistic measure of feasibility from the patient’s perspective, but provides an indication of 
the acceptability of the instruments using the level of missing data as a proxy.  Completion 
rates of 95% or more were considered high.36  
 
The analysis was carried out for both the common mental health condition group- where the 
measures were completed using self-report- and also for the schizophrenia and personality 
disorders samples- where the measures were interviewer-administered, but may still lead to 
missing data.  It is important to note that although the level of completion may act as a proxy 
for feasibility, the results need to be interpreted with caution as it is not always clear how 
many questionnaires respondents have completed before those assessed in this study, the 
impact of fatigue on missing data, and other pressures placed on respondents to complete 
the measures. 
 Validity  
Validity assesses how well an instrument measures what it was intended to measure, and is 
assessed in comparison to other instruments and clinical indicators that have been validated 
for use in the field.  The validity of an instrument is assessed in light of the fact that there is 
no gold standard for the measurement of HRQL in mental health.  This means that we can 
assess a range of indicators of validity, but cannot fully prove the validity of an instrument. 
We assessed validity by carrying out tests of discriminant or known group validity, and 
convergent validity. 
 
Convergent validity 
The convergence between the generic PBMs and the condition specific instruments was 
tested using Pearson’s correlation coefficients and locally weighted scatterplot smoothing 
(LOWESS)37 techniques.  Good correlations indicate that the PBMs can measure mental 
health-related factors that are assessed by the validated condition-specific instruments. 
Correlations are considered weak if scores are <0.3, moderate if scores are ≥0.3 and <0.7, 
and strong if scores are  ≥0.7.  
 
LOWESS is a form of non parametric regression that attempts to capture general patterns in 
the relationship between two measures without making assumptions about the actual 
relationship between the variables, and demonstrates the relationship between the 
measures across the scoring range. LOWESS plots a line on a scatterplot on the central 
tendency between the two variables thereby visualising the relationship between these 
variables. 
 
In the common mental health condition and mixed diagnosis groups, the convergent validity 
of EQ-5D was assessed in comparison to the HADS-T, HADS-A and HADS-D, and the SF-
6D was assessed in comparison to the CORE-OM clinical and dimension scores.  In the 
schizophrenia analysis, the EQ-5D was assessed in comparison to the PANSS and the 
BPRS-E, and the SF-6D was assessed in comparison to the BPRS-E. For personality 
disorders, tests of convergence between the EQ-5D and SIDP-IV were not carried out, as 
the SIDP-IV assesses fourteen personality disorders individually on a four point scale, and 
we did not believe that correlating each disorder indicator with the EQ-5D index score was 
appropriate. 
 
 
Discriminant validity 
The discriminant or known group validity analysis assesses the ability of the generic PBMs 
to discriminate between condition-specific severity groups. For the common mental health 
and mixed diagnosis samples, the discriminant validity of EQ-5D was assessed using 
HADS-A and HADS-D cut-off points indicating probable anxiety or depression (a score of ≥ 
11).  For SF-6D, discriminant validity was assessed using CORE-OM clinical cut off points 
(where a score of > 10 indicates clinical concerns) 
 
One-way ANOVA was used to assess the magnitude of differences in the PBM scores 
across the severity groups.  Standardised effect sizes across severity sub-groups were 
assessed (calculated as the difference in mean scores between two adjacent severity sub-
groups divided by the standard deviation of scores for the milder of the two sub-groups). 
Effect sizes of less than 0.2 are small, 0.5 moderate, and 0.8 large.38 However, care must be 
taken when comparing these between preference-based measures, since more is not 
necessarily better in terms of effect sizes (that simply indicate whether the generic PBM 
reflects what appears to be an important difference).39  
 
The discriminant validity of the EQ-5D and SF-6D in the QUATRO schizophrenia sample 
used BPRS-E cut-offs (31 for ‘mildly ill’ , 41 for ‘moderately ill’,  53 for ‘markedly ill’ and 70 for 
‘extremely ill’).40  For the MATISSE sample, PANSS cut-offs (58 for “mildly ill”, 75 for 
“moderately ill”, 95 for  “markedly ill” and 116 for “severely ill”)41 were used.  For the 
SCEPTRE analysis, the discriminant validity of the EQ-5D was tested using diagnosis 
categories (defined as those with and without a personality disorder diagnosis, and also the 
number of personality disorders diagnosed). 
 
Responsiveness 
The responsiveness analysis assessed the sensitivity of EQ-5D and SF-6D to change in 
health status in comparison to the condition-specific PROMS.  This included assessing floor 
and ceiling effects and the magnitude of the change in scores between two study time 
points. Floor (lowest possible score) and ceiling (highest possible score) effects impact the 
ability of the measure to detect deterioration or improvements in health respectively.  The 
magnitude of change in scores is assessed before and after an intervention.  We accept that 
this is a crude indicator of change.  However for each study there was evidence of change 
between baseline and follow up. Where there has been an overall change then this should 
be reflected in by a significant change in the generic PBM score.  
 
The magnitude of change reflected in the measures between the time points was assessed 
using the standardised response mean (SRM) statistic (calculated by dividing the mean 
change on the measure by the standard deviation of the change),42 and the effect size. 
Again, effect sizes of less than 0.2 are small, 0.5 moderate, and 0.8 large.38 Responsiveness 
analysis was not carried out for the mixed common mental health problem and personality 
disorder sample as only baseline data was available for the POPMACT study. 
 
Results   
Sample characteristics 
Demographic characteristics available for each dataset are displayed in Table 1.   The 
POPMACT sample has lower EQ-5D and HADS scores than the AHEAD sample, indicating 
higher levels of quality of life impairment and anxiety and depression (Table 2).  SF-6D and 
CORE-OM scores indicate that the IAPT sample displays lowers levels of quality of life and 
functioning than the PONDeR sample.  For the schizophrenia sample, baseline EQ-5D 
scores indicate that those in the MATISSE and QUATRO samples have similar quality of life 
levels.  Those in the personality disorder (SCEPTRE) sample display lower quality of life as 
measured by the EQ-5D than the schizophrenia sample 
 
Feasibility 
Completion rates for assessment of feasibility are reported in Table 2. 
 
Common mental health conditions 
The AHEAD dataset demonstrates that both the EQ-5D and HADS had completion rates in 
the high range (97.86% to 99.08%) at baseline, for those participants who returned a 
questionnaire.  Across the IAPT and PONDeR datasets, the completion rates for SF-6D and 
CORE-OM for those who returned a questionnaire at baseline were between 93.74% and 
97.86%.   
 
Common mental health and personality disorders  
The EQ-5D and HADS were fully completed by more than 99% of the POPMACT sample 
who were interviewed 
 
Schizophrenia and personality disorders 
The EQ-5D completion rates (for those taking part at baseline where the measures were 
collected via interview) ranged between 96.33% and 98.56%.  This was slightly higher than 
the SF-6D which had a completion rate of 93.64%.  The condition specific PANSS and 
BPRS-E also had high completion rates (98.56% and 99.27%, respectively). 
 
Personality disorders 
The completion rate of the interviewer completed EQ-5D was 99.34%. 
 
Convergent validity  
Common mental health conditions 
The correlation between the EQ-5D and HADS-T, HADS-A and HADS-D indicate a 
moderate level of convergence (Table 3). Negative correlations were produced, as a high 
score on the generic PBM and a low score on the condition specific measure indicates better 
health status. The SF-6D is correlated with the CORE-OM clinical score and functioning, 
wellbeing and symptoms domain scores in the moderate to strong range across both 
samples.  The correlation with the risk domain score was moderate for the IAPT sample and 
low for the PONDeR sample.  All correlations were significant (p<0.01).   
 
Figure 1 displays scatterplots of the relationship between the generic and condition specific 
measures and the LOWESS fit lines.  The lines demonstrate that the relationship between 
the EQ-5D and HADS differed across the severity scale (the concordance between the 
measures is better at the less severe end of the scale). The relationship between the SF-6D 
and CORE-OM was more consistent across the severity scale, and was similar for both the 
IAPT and PONDeR samples. 
 
Common mental health and personality disorders  
The correlation between the EQ-5D and HADS-T, HADS-A and HADS-D indicates a 
moderate level of convergence (p<0.01; Table 3). Again, the LOWESS fit line for the 
POPMACT data indicates that the relationship between the EQ-5D and HADS differed 
across the severity scale, where the concordance between the measures was higher at the 
less severe end of the scale. 
 
Schizophrenia 
The correlations between EQ-5D and condition-specific measures varied across the two 
schizophrenia samples. Correlations with the BPRS-E in the QUATRO sample were 
moderate for the total score and the depression and positive symptom dimensions; while 
they were weak for the other dimensions (Table 4). Correlations with the PANSS and the 
MATISSE sample were weak, indicating little convergence.  
 
The correlations between SF-6D and BPRS-E follow a similar pattern to those of the EQ-5D 
although the correlations were smaller in magnitude, with weak correlations across most of 
the dimensions apart from depression (Table 4). There was therefore poor evidence of 
convergence for SF-6D. 
 The LOWESS lines for the QUATRO sample (that completed both EQ-5D and SF-6D) 
demonstrate a tendency for the generic PBM scores to increase as scores on the BPRS-E 
decrease (equivalent to less severe problems on both measures). However, the EQ-5D 
displayed a large ceiling effect, meaning that a score of 1 on EQ-5D was associated with a 
wide range of BPRS scores.  There was a trend towards a linear relationship between the 
EQ-5D and PANSS, and a large EQ-5D ceiling effect.  
 
Personality disorders 
Tests of convergence between the EQ-5D and SIDP-IV were not carried out. 
 
Discriminant validity 
Common mental health conditions 
EQ-5D index scores were significantly higher in the no case group (a score of 0-10) than the 
probable case group (a score of 11+) as measured by both the HADS-A and HADS-D for the 
AHEAD sample (p=0.002).  In both the IAPT and PONDeR samples, the SF-6D index score 
was significantly higher in the non clinical population in comparison to the clinical group as 
measured by CORE-OM (both P<0.001; Table 5).   
 
Common mental health and personality disorders  
For the POPMACT sample, the EQ-5D index scores were significantly higher in the no case 
group than the probable case group for both the HADS-A (p<0.001) and HADS-D (p<0.001). 
 
Schizophrenia 
EQ-5D scores were significantly higher for those with a lower level of severity as measured 
by both the BPRS-E (p<0.001) and the PANSS (p=0.003) in the two schizophrenia samples 
(Table 6). Effect sizes across the severity sub-groups were moderate in size for the BPRS-E 
and small for the PANSS indicating that the EQ-5D can discriminate between severity 
groups to some extent.  
 
The SF-6D scores significantly discriminated between BPRS-E severity groups, with scores 
in the most severe group higher than those for the EQ-5D. Effect sizes indicate that the 
difference between the mild and moderate severity groups was small. 
 
Personality disorders 
For the SCEPTRE data, EQ-5D scores varied according to the number of diagnoses, with 
lower scores for those with one or more personality disorders (Table 6). However, these 
differences were not statistically significant (P=0.202). There is a significant difference in 
EQ-5D scores between samples with different types of personality disorder (p=0.042), but 
this is difficult to interpret. 
 
Responsiveness 
Common mental health conditions 
At baseline EQ-5D and HADS displayed no evidence of floor or ceiling effects.  However, at 
follow up there was evidence of a large ceiling effect for EQ-5D and a moderate ceiling effect 
for HADS-D (Table 7).  The SRM for EQ-5D was in the moderate range and for the HADS 
was large.  This demonstrates that the HADS was more responsive in the AHEAD sample. 
 
The SF-6D displayed a small ceiling effect for the PONDeR data.  The SRM statistics for the 
SF-6D and CORE-OM in the IAPT validation sample were in the moderate range.  For the 
PONDeR sample, the SF-6D SRM was in the large range, in contrast to the CORE-OM 
dimensions which were in the small range.  Therefore, there was evidence that the 
responsiveness of SF-6D was in the same range as the CORE-OM for depression, and may 
even be more responsive in post-natal depression.  
 
Common mental health and personality disorders 
Responsiveness analysis was not carried out, as only baseline data was available. 
 
Schizophrenia 
For the QUATRO and MATISSE samples, the EQ-5D displays no evidence of floor effects at 
baseline, but there is evidence of a large ceiling effect at both time points (Table 7). Mean 
change in the QUATRO sample is statistically significant, but the effect sizes and SRM 
statistics are less than 0.2 (below the clinically significant range).  The BPRS-E has a larger 
effect size and SRM statistic which indicates that EQ-5D was less responsive in this 
particular sample. The SF-6D displays no evidence of floor or ceiling effects in the QUATRO 
sample. Mean change on the SF-6D is smaller than the EQ-5D but the effect size and SRM 
statistics were consistently below 0.2.   
 
In the MATISSE sample, mean change for EQ-5D is not statistically significant, leading to a 
small effect size and SRM statistics. The PANSS demonstrates statistically significant mean 
change, however, the effect sizes are in the low range.  The small change demonstrated 
indicates that neither the EQ-5D nor PANSS are responsive in the MATISSE schizophrenia 
sample.  
 
Personality disorders 
In the SCEPTRE sample, EQ-5D displays minimal floor and ceiling effects and shows good 
responsiveness with moderate effect sizes and SRMs at 12 months.  
 
Discussion 
Seven datasets were used to examine the psychometric validity of the EQ-5D and SF-6D 
across a range of mental health conditions in comparison to widely used condition specific 
measures. The results suggest that the generic PBMs are valid for use in common mental 
health conditions and mixed diagnoses groups in comparison to existing measures of mental 
health, and there is some evidence of responsiveness to change in health status over time.  
For personality disorders, the results were also positive, as EQ-5D was shown to 
discriminate between severity groups, and respond to change over time.  In comparison, the 
evidence in schizophrenia was less clear. There was some support for construct validity 
across related domains and some evidence of discriminative properties.  However 
responsiveness to change was low.   
 
Evidence for the psychometric validity of the EQ-5D and SF-6D in common mental health 
patient samples is consistent with previous empirical work in mild depression and anxiety 
samples.6,8,9 A probable explanation for these positive findings is that both descriptive 
systems include mental health specific questions that are relevant to depression and anxiety.  
Therefore the measures may have a level of sensitivity to the conditions and some level of 
association with the widely used comparison measures. We have also established some 
evidence that the EQ-5D is valid in a sample with common mental health and personality 
disorder diagnoses leading to self harm.  This group could be seen as a moderately severe 
sample (which is supported by the higher HADS scores in comparison to the AHEAD 
sample).  There were some differences between the performance of the EQ-5D and SF-6D 
in common mental health samples, but direct comparisons were difficult because the 
analysis of each measure was carried out using different samples with different 
characteristics. The growing evidence base regarding the validity of the instruments 
indicates that EQ-5D and SF-6D can be considered valuable for the use in the economic 
evaluation of interventions for common mental health disorders. 
 
The positive results found for the personality disorders sample is in line with past work in the 
area12 which found that the EQ-5D correlates with condition specific indicators, and 
responds to change over time.  This indicates that EQ-5D has some level of validity for use 
in the assessment of interventions for personality disorders. We compared EQ-5D to a 
diagnosis instrument completed by clinicians, and it would be useful to use a self or 
interviewer administered PROM as a comparator.   
 
Past work has found mixed evidence for the performance of generic PBMs in schizophrenia. 
10 In this study we have established evidence for and against the validity of the generic 
PBMs in schizophrenia, and there was mixed evidence regarding the ability of the measures 
to reflect schizophrenia-specific symptoms. The EQ-5D may be related to some condition 
specific domains (for example depression) but not others (such as positive symptoms), and 
again this may be linked to the classification system which directly assesses anxiety and 
depression, but may not be sensitive to other schizophrenia-specific domains.  Direct 
comparisons between the EQ-5D and SF-6D were only possible for the QUATRO study, 
which found that neither instrument converges with the condition specific measure (but this 
may not be expected), and neither instrument responds to change over time at the same 
level that is reflected in the condition-specific indicators.  The low level of responsiveness for 
EQ-5D may be due to the large ceiling effect at baseline which may impair its ability to detect 
change over time. The mixed evidence regarding the schizophrenia sample means that the 
EQ-5D and SF-6D should be used with caution in these groups, and further research in 
other samples to investigate psychometric performance in more detail is warranted.  
 
Psychometric analysis of the PBMs is one method of assessing validity, and should be 
considered alongside other types of evidence to establish a detailed picture of the 
performance of these measures.  For example this work should be considered alongside 
systematic reviews9,10 and qualitative work assessing the content validity and acceptability of 
the instruments from the patient perspective.  This allows for detailed insight into the 
performance of the instruments and will inform future work to increase the sensitivity and 
validity of measurement across a range of mental health conditions. There are a number of 
ways in which the sensitivity of the instruments could be improved.  This includes the 
development of ‘bolt on’ dimensions for the generic PBMs to directly assess particular 
conditions.  Alternatively, condition specific PBMs could be developed either using standard 
instrument development procedures or by adapting an existing condition specific instrument, 
examples of which are available for other neurological and mental health conditions.43-46 A 
five level version of the EQ-5D has been developed,47 and it is possible that this version may 
be more sensitive to different severity levels and change across time.  Further research 
could assess the validity of the five-level version in patients with mental health conditions.  
 
This study has a number of limitations.  Firstly, as in much psychometric validation, there is 
no ‘gold standard’ measure of HRQL against which to compare the generic PBMs.  This 
means that the analysis provides a guide to the performance of the measure, but is limited 
by the validity of the comparison indicator and the constructs tested by this instrument.  This 
means that the results are open to interpretation and opinion.  In this study it can be argued 
that the generic PBMs are compared against indicators that have some level of validity in the 
populations tested,24,30,31 and this allows some inferences to be drawn.  However, the 
different scope of the condition specific and generic measures and the different development 
procedures used, suggests that some level of divergence is to be expected. Furthermore, 
the condition specific measures used here assess specific symptoms, in comparison to the 
generic PBMs which include dimensions of health-related quality of life.  Therefore, we may 
not expect especially close concordance between them. The same concerns apply when 
testing responsiveness, and it is important to consider if the measures of health change are 
themselves valid.  
 
Secondly, we used the level of missing data as a form of proxy for the feasibility of the 
measure in mental health populations.  This approach can be criticised, as the external 
pressures and expectations felt by respondents in trials to complete the measures is unclear.  
There are a range of reasons why measures are incomplete that do not specifically relate to 
the measure, including severity of the mental health condition, fatigue, lack of motivation, or 
the position of the questionnaires in the study. 
 
The inferences that can be drawn from the results are also limited to the mental health 
conditions included in the seven datasets, and the generalisability to other populations 
should be investigated.  Moreover, the differing levels of performance in terms of construct 
validity, convergent validity, and responsiveness also reflect the systematic variance 
attributable to different types of data used in this study, the different patient populations, and 
different study designs. Furthermore, only one dataset included both EQ-5D and SF-6D.  
This means that the level of transferability to other mental health samples with similar 
diagnoses but different characteristics is unclear, and full comparisons between the generic 
PBMs are not possible.  Further work into the performance of the EQ-5D and SF-6D in 
mental health conditions should focus on replicating the current analysis on different mental 
health conditions using different condition-specific measures and indicators, and directly 
comparing the generic PBMs. It is also possible that due to their generic nature, the PBMs 
are picking up co morbidities, however this is difficult to test in the data available, as 
indicators of other conditions (including physical conditions) were not available. It would be 
useful to attempt to assess the impact of comorbidities on utility scores in mental health 
populations.  
 
In summary, we have reported the first work to test the psychometric performance of two 
widely used generic preference based measures of health related quality of life across a 
range of populations with mental health disorders using data from a variety of sources.  The 
study adds to the evidence base about the mental health conditions where the measures 
can be used in the economic evaluation of new and emerging interventions. It also highlights 
possible areas where new preference based measures, or additions to existing measures, 
would improve the measurement of HRQL in mental health. 
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Table 1: Summary of datasets and measures used for analysis 
Dataset Description Time points 
used 
PBM Condition specific Characteristics  
     N (baseline) Age (m,sd) Female (%) 
Common mental health        
Assessing Health Economics of Antidepressants 
(AHEAD)
13 
RCT of the cost effectiveness of antidepressants 
(three time points). Sample includes common 
mental health concerns - depression, mixed 
anxiety and depressive disorders (MADD), and 
phobias 
Baseline 
6 months 
12 months 
EQ-5D HADS 327 
 
43.1 (15.4) 67.0 
Psychological interventions for postnatal depression 
(PONDeR)
14 
Study of two psychologically informed 
interventions for women with post-natal depression 
Baseline 
6 months 
12 months  
SF-6D CORE-OM 2,640 31.5 (5.1) 100 
Improving Access to Psychological Therapies cohort study 
(IAPT)
15 
Evaluation of the outcomes from two IAPT 
demonstration sites. Sample reports common 
mental health condition. 
Baseline 
4 months 
8 months 
SF-6D CORE-OM 527 40.9 (14.2) 72.3 
Common mental health and personality disorders        
POPMACT
16,17 
RCT of manual-assisted cognitive therapy (MACT) 
versus treatment as usual (TAU) in recurrent self-
harm. Sample includes patient with diagnoses of 
common mental health conditions and personality 
disorders leading to self harm 
Baseline EQ-5D HADS 480 32.0 (11.2)  
Schizophrenia/personality disorders        
Quality of Life following Adherence Therapy (QUATRO)
18 
Multicounty RCT of adherence therapy in patients 
with a clinical diagnosis of schizophrenia for 
needed continuing antipsychotic medication for at 
least a year from assessment, and had evidence 
of clinical instability in the year before assessment. 
Previous work comparing EQ-5D and SF-6D 
utilities using this data (McCrone et al., 2009). 
 EQ-5D 
SF-6D 
BPRS-E 409 41.5 (11.5) 59.9 
Multi-centre study of Art Therapy In Schizophrenia - 
Systematic Evaluation (MATISSE)
19 
RCT of group art therapy for people with a clinical 
diagnosis of schizophrenia. 
Baseline  
12 months 
EQ-5D PANSS 417 41.0 (11.5) 33.3 
Study of cost effectiveness of personality disorder 
treatment (SCEPTRE)
20
  
Dutch study of adult patients with personality 
disorders (UK EQ-5D tariff used for comparability).  
Baseline  
12 months 
EQ-5D DSM-IV personality 
disorder category 
932 35.1 (9.8) 68.1 
Table 2: Descriptive statistics and completion rates 
 N (completing 
measure) 
Mean SD Completion (%) 
Common mental health – EQ-5D     
AHEAD     
EQ-5D                               Baseline 320 0.604 0.264 97.86 
6m  174 0.752 0.257  
12m  164 0.777 0.249  
HADS-A                            Baseline 324 13.11 3.48 99.08 
6m 202 8.78 3.54  
12m 169 8.30 3.59  
HADS-D                            Baseline 324 10.50 3.87 99.08 
6m 202 4.94 3.92  
12m 169 4.34 3.99 98.83 
Common mental health – SF-6D     
IAPT     
SF-6D                               Baseline 504 0.613 0.13 95.6 
4 months 425 0.645 0.14  
8 months 390 0.668 0.15  
CORE-OM clinical score Baseline 494 20.06 7.81 93.74 
4 months 409 16.58 8.53  
8 months 403 15.09 8.83  
PONDeR     
SF-6D                               Baseline 2600 0.669 0.09 97.82 
6 months 2614 0.822 0.14  
12 months 1697 0.839 0.13  
CORE-OM clinical             Baseline 2640 5.23 4.97 99.32 
6 months 2641 4.73 4.91  
12 months 1713 4.52 4.85  
Common mental health and 
personality disorders 
    
POPMACT     
EQ-5D                               Baseline  476 0.503 0.320 99.20 
HADS-A                            Baseline 479 14.13 3.94 99.80 
HADS-D                            Baseline 478 11.22 4.58 99.58 
Schizophrenia     
MATISSE     
EQ-5D                               Baseline 409 0.676 0.271 98.08 
12 months 357 0.678 0.297  
PANSS Total score           Baseline 411 79.45 24.19 98.56 
12 months 334 76.15 27.11  
QUATRO     
EQ-5D                               Baseline 394 0.679 0.291 96.33 
12 months 367 0.710 0.286  
SF-6D                               Baseline 383 0.668 0.125 93.64 
12 months 367 0.682 0.134  
BPRS-E Total                   Baseline 406 45.17 13.02 99.27 
12 months 371 37.71 10.54  
Personality disorders     
SCEPTRE     
EQ-5D                               Baseline 899 0.566 0.284 99.34 
12 months  693 0.741 0.249  
 
  
Table 3: Convergent validity of EQ-5D and SF-6D in common mental health, and joint diagnosis 
samples 
 Common mental health  Joint 
diagnosis  
 AHEAD IAPT PONDeR POPMACT 
 EQ-5D index SF-6D index SF-6D index EQ-5D index 
HADS-T -0.36** - - -0.49** 
HADS-A -0.35** - - -0.39** 
HADS-D -0.22** - - -0.46** 
CORE-OM      
Clinical score - -0.61** -0.51** - 
Functioning score - -0.51** -0.46** - 
Symptoms score - -0.64** -0.53** - 
Wellbeing score  - -0.51** -0.45** - 
Risk score - -0.37** -0.16 - 
**= significant at 0.01 
Table 4: Convergent validity of EQ-5D and SF-6D in schizophrenia 
  QUATRO  MATISSE 
  EQ-5D index SF-6D index EQ-5D index 
BPRS-E total  -0.42** -0.29** - 
BPRS-E disorganisation   -0.22** -0.13** - 
BPRS-E depression   -0.43** -0.34** - 
BPRS-E negative symptoms   -0.21** -0.12** - 
BPRS-E positive symptoms   -0.31** -0.20** - 
     
PANSS total  - - -0.16** 
PANSS positive  - - -0.12 
PANSS negative  - - -0.05 
PANSS general symptoms  - - -0.21** 
**= significant at 0.01 
 
  
  
 
  
Table 5: Discriminant validity of EQ-5D and SF-6D in common mental health and joint 
diagnosis samples 
Data and indicator Groups  n  
Common mental health – EQ-5D (AHEAD)    
HADS-A caseness No case Mean (sd) 98 0.671 (0.25) 
 Probable case Mean (sd) 219 0.573 (0.27) 
  P value  0.002 
  ES  0.37 
HADS-D caseness No case Mean (sd) 163 0.677 (0.24) 
 Probable case Mean (sd) 154 0.525 (0.27) 
  P value  0.000 
  ES  0.60 
Common mental health - SF-6D (IAPT)    
CORE-OM clinical Non clinical Mean (sd) 53 0.740 (0.11) 
 Clinical Mean (sd) 422 0.597 (0.12) 
  P value  0.000 
  ES  1.24 
SF-6D sample (PONDeR)    
CORE-OM clinical Non clinical Mean (sd) 2241 0.683 (0.08) 
 Clinical Mean (sd) 399 0.595 (0.07) 
  P value  0.000 
  ES  1.16 
Common mental health and personality disorders - 
EQ-5D  (POPMACT) 
   
HADS-A caseness No case Mean (sd) 84 0.718 (0.28) 
 Probable case Mean (sd) 392 0.457 (0.31) 
  P value  0.000 
  ES  0.88 
HADS-D caseness No case Mean (sd) 210 0.622 (0.30) 
 Probable case Mean (sd) 265 0.410 (0.30) 
  P value  0.000 
  ES  0.71 
 
 
  
Table 6: Discriminant validity of EQ-5D and SF-6D in schizophrenia and personality disorders 
        
    EQ-5D   SF-6D  
Variable Groups  N Mean (sd) ES N Mean (sd) ES 
Schizophrenia        
QUATRO        
BPRS-E None/mild (24-31) 56 0.831 (0.16)  56 0.727 (0.09)  
 Moderate (32 – 41) 112 0.744 (0.23) 0.54* 112 0.682 (0.12) 0.47 
 Marked (42 – 53) 119 0.652 (0.28) 0.40* 119 0.664 (0.12) 0.16 
 Severe (>53) 88 0.543 (0.36) 0.39 88 0.625 (0.13) 0.31 
  p=0.000 p=0.000 
        
MATISSE        
PANSS Normal/mild (30 -58) 86 0.747 (0.24)     
 Moderate (59 – 75) 114 0.693 (0.23) 0.23    
 Marked (76 – 95) 112 0.660 (0.27) 0.14    
 Severe (>95) 92 0.606 (0.33) 0.20    
  p=0.003    
        
Personality 
disorders        
Number of 
diagnosis 
 
No Personality Disorder 84 0.648 (0.24)     
 1 Personality Disorder 248 0.606( 0.27) 0.18    
 2 Personality Disorder 95 0.549 (0.30) 0.21    
 3 Personality Disorder 42 0.493 (0.29) 0.18    
 ≥4 Personality Disorders 41 0.416 (0.27) 0.27    
  p=0.202    
 
       
Diagnosis 
a
 None 113 0.657 (0.23)     
 Borderline 41 0.581 (0.29) 0.32
b 
   
 Avoidant 69 0.638 (0.25) 0.08
 b
    
 Obsessive-compulsive 55 0.578 (0.27) 0.34
 b
    
 Depressive 60 0.525 (0.28) 0.56
 b
    
 Not otherwise specified 142 0.616 (0.29) 0.17
 b
    
  p=0.042    
* p<0.05 in test of difference between adjacent severity groups 
a – Sample of those with a single diagnosis 
b – compared to the group with no personality disorder 
  
  
Table 7: Responsiveness of generic and condition specific measures 
Measure % at floor % at ceiling Mean 
change 
ES SRM T-test 
 T0 T1 T0 T1     
Common mental health         
EQ-5D 
AHEAD (n=164) 
        
                                      EQ-5D 0 0 2.19 34.15 0.17 (0.38) 0.64 0.45  
HADS-T 0 0 0 0 -10.74 (8.83) -1.85 -1.22  
HADS-A 0 0 0 0 -4.81 (4.98) -0.70 -0.97  
HADS-D 0 0 0.62 14.79 -5.93 (5.67) -0.68 -1.05  
SF-6D 
IAPT (n=390) 
        
                    SF-6D 0 0 0 1.54 -0.06 (0.12) 0.46 0.50  
CORE-OM clinical score 0 0 0 0 -4.71 (6.71) 0.60 -0.70  
Functioning score 0.41 0 0.82 1.50 -0.37 (0.75) 0.44 -0.49  
Symptoms score 1.22 1.24 0.20 0.50 -0.58 (0.84) 0.62 -0.70  
Wellbeing score  7.46 2.72 0.81 3.95 -0.57 (0.97) 0.63 -0.59  
Risk score 0.2 0 39.27 54.48 -0.18 (0.55) 0.22 -0.32  
PONDeR (n=1,697)         
                  SF-6D 0 0 0 18.33 0.17 (0.13) 1.89 1.31  
CORE-OM clinical score 0 0 3.48 7.82 -0.58 (4.69) -1.16 -0.12  
Functioning score 0 0.06 12.35 17.24 -0.04 (0.57) -0.06 -0.07  
Symptoms score 0 0 8.60 16.13 -0.10 (0.57) -0.17 -0.18  
Wellbeing score  0 0.06 20.14 29.77 -0.10 (0.76) -0.13 -0.13  
Risk score 0.04 0 90.23 89.55 -0.01 (0.20) -0.07 -0.05  
Schizophrenia         
QUATRO  (n=328)         
EQ-5D 0 0 16.8 20.7 0.035 (0.29) 0.12 0.12 0.026 
SF-6D 0 0.3 0.6 0.9 0.014 (0.12) 0.12 0.12 0.027 
BPRS-E 1.2 4.3 0 0 -7.60 (13.06) -0.58 -0.58 0.000 
BPRS-E positive  17.1 26.8 0 0 -3.04 (5.70) -0.52 -0.53 0.000 
BPRS-E negative  21.3 35.1 0 0 -1.37 (4.06) -0.33 -0.34 0.000 
BPRS-E disorganisation  20.1 36.9 0 0 -1.62 (4.22) -0.42 -0.38 0.000 
BPRS-E depression  0 15.9 0 0 -1.90 (5.41) -0.34 -0.35 0.000 
MATISSE (n=321)         
EQ-5D 0 0 16.8 20.2 -0.005 (0.29) -0.02 -0.02 0.767 
PANSS 0 0 0 0 -3.41 (20.85) -0.16 -0.14 0.004 
PANSS positive 2.5 3.4 0 0 -0.93 (6.17) -0.15 -0.15 0.007 
PANSS negative 2.2 4.0 0 0.3 -0.78 (6.48) -0.12 -0.11 0.031 
PANSS general symptoms 0.3 0 0 0 -1.21 (10.65) -0.11 -0.10 0.042 
Personality  disorders         
SCEPTRE (n =679)         
EQ-5D 0 0 4.0 21.6 0.170 (0.29) 0.61 0.58 0.000 
N: Those who completed both measures at all time points   
ES/SRM size – small: >0.2 ≤0.5, moderate: >0.5 <0.8, large: ≥0.8; T0: Baseline, T1: Follow up 
  
Figure 1: Scatterplots/LOWESS lines for the common mental health and mixed diagnosis 
conditions 
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Figure 2: Scatterplots/LOWESS lines for the schizophrenia and personality disorder samples    
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